Değer202020212022202320242025TTMSatış/genel/idari giderler11.29 B15.23 B18.42 B19.22 B19.98 B19.93 B—Araştırma ve geliştirme5.99 B9.74 B9.76 B10.94 B13.58 B14.23 B—Faaliyet karı5.16 B1.06 B3.76 B8.19 B10 B13.74 B—Faaliyet Dışı Gelir, Toplam———————Faiz gideri (aktifleştirilmiş faizler düşüldükten sonra)———————Faaliyet Dışı Gelir (Faiz Giderleri Hariç)———————Olağandışı gelirler/giderler———————Vergi öncesi kar3.92 B265 M2.5 B6.9 B8.69 B12.4 B—Kazançlardaki özsermayeler———————Vergiler772 M380 M792 M938 M1.65 B2.17 B—Kontrol gücü olmayan/azınlık payı52 M3 M5 M6 M6 M8 M—Vergi sonrası diğer gelirler/giderler———————Durdurulan faaliyetler öncesi net kar3.14 B115 M3.29 B5.96 B7.04 B10.23 B—Durdurulan faaliyetler———————Net kar3.14 B115 M3.29 B5.96 B7.04 B10.23 B—Seyreltme ayarlaması———————İmtiyazlı temettüler———————Adi hisse senedi sahiplerine düşen seyreltilmiş net kar———————Temel hisse başına kazanç (Temel EPS)———————Seyreltilmiş hisse başına kazanç (Seyreltilmiş EPS)———————Dolaşımdaki ortalama adi hisse senedi sayısı———————Dolaşımdaki seyreltilmiş hisse senedi sayısı———————FAVÖK———————FVÖK———————Gelir maliyeti5.3 B12.44 B12.39 B8.27 B10.21 B10.63 B—Satılan malların diğer maliyeti———————Amortisman ve itfa (nakit akışı)———————
AstraZeneca PLC - American Depositary Shares
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, UK; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje.